Eli Lilly extends expiration of tender offer to acquire Dice Therapeutics

Eli Lilly (LLY) announced the extension of the expiration of the tender offer to acquire all of the issued and outstanding shares of common stock of Dice Therapeutics (DICE), for a purchase price of $48 per share in cash, without interest and less any applicable tax withholding. The company said, “The tender offer, which was previously scheduled to expire one minute past 11:59 p.m., Eastern time, on July 28, 2023, has been extended until one minute past 11:59 p.m., Eastern time, on Aug. 8, 2023, unless the tender offer is further extended or earlier terminated. The proposed acquisition is expected to close in the third quarter of 2023, subject to customary closing conditions, including the receipt of required antitrust clearance and the tender of at least a majority of the outstanding Shares as of the expiration of the tender offer.”